Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation.
10.4070/kcj.2009.39.5.185
- Author:
Jeong Hwan PARK
1
;
Yong Seog OH
;
Ji Hoon KIM
;
Woo Baek CHUNG
;
Su Sung OH
;
Dong Hyun LEE
;
Yun Seok CHOI
;
Woo Seung SHIN
;
Chul Soo PARK
;
Ho Joong YOUN
;
Wook Sung CHUNG
;
Man Young LEE
;
Ki Bae SEUNG
;
Tae Ho RHO
;
Jae Hyung KIM
;
Soon Jo HONG
Author Information
1. Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. oys@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Atrial fibrillation;
Catheter ablation;
Angiotensin-converting enzyme inhibitors;
Angiotensin II type 1 receptor blockers
- MeSH:
Angiotensin II Type 1 Receptor Blockers;
Angiotensin-Converting Enzyme Inhibitors;
Angiotensins;
Atrial Fibrillation;
Catheter Ablation;
Follow-Up Studies;
Heart Atria;
Humans;
Multivariate Analysis;
Peptidyl-Dipeptidase A;
Recurrence
- From:Korean Circulation Journal
2009;39(5):185-189
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: It is known that angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers (ACEIs and ARBs, respectively) are effective in preventing atrial fibrillation (AF) in high-risk patients. However, it is not known whether ACEIs and ARBs are effective in preventing the recurrence of AF after catheter ablation. SUBJECTS AND METHODS: One hundred fifty-two patients (mean age, 57+/-10 years; M : F=94 : 58) who underwent catheter ablation due to drug-refractory paroxysmal (mean age, 57+/-10 years; M : F=58 : 43) or persistent AF (mean age, 56+/-10 years; M : F=36 : 15) were enrolled. We compared the recurrence rates between the groups with and without ACEIs or ARBs use in paroxysmal and persistent AF. The mean duration of follow-up was 18+/-14 months. RESULTS: The overall recurrence rate after ablation therapy was 26% (n=39). The recurrence rate was significantly decreased in the patients with persistent AF with the use of ACEIs or ARBs (12.1% vs. 61.1%, p<0.01), but this difference was not observed in the patients with paroxysmal AF (24.2% vs. 22.9%, p=0.87). In patients with persistent AF with and without recurrence, the size of the left atrium (44.2+/-8.4 mm vs. 44.3+/-5.8 mm, respectively, p=0.45) and the ejection fraction (62+/-6.5% vs. 61.5+/-6.2%, respectively, p=0.28) were not significantly different. In multivariate analysis, the use of ACEIs or ARBs was independently associated with recurrence after adjusting for the size of the left atrium and the ejection fraction {odds ratio (OR)=0.078, 95% confidence interval (CI)=0.02-0.35, p<0.01}. CONCLUSION:ACEIs and ARBs were shown to be effective in preventing AF recurrence after catheter ablation in patients with persistent AF.
